Passaggio di venlafaxina nel latte materno durante l’allattamento: rilevanza della sua misura in laboratorio
Venlafaxine excretion in breast milk during 12-months of lactation: the relevance of the laboratory measurement

AUTORI

ABSTRACT

Venlafaxine excretion in breast milk during 12-months of lactation: the relevance of the laboratory measurement

A woman with pre-existing depression on treatment with venlafaxine at 75 mg daily underwent a caesarean section due to alteration of the cardiotocography trace. No sign of poor neonatal adaption was observed in the newborn due to the antidepressant exposition. The mother was suggested to breast feed the baby and continue with the antidepressant therapy. Drug concentrations of venlafaxine in mother and neonate plasma and in mother milk at birth and during follow up visits were determined. A significant reduction in the plasma venlafaxine concentrations from the mother was observed at birth compared with the 3rd trimester (77 versus 245 ng/mL), with a full recovery at month 2 after delivery (226 ng/mL). Plasma venlafaxine concentrations from the newborn were high at birth (185 ng/mL) and progressively declined with time, despite the high milk drug concentrations measured throughout the observational period. During the one-year follow-up, no symptoms related to venlafaxine-toxicity were observed in the baby-girl.

BIBLIOGRAFIA